Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 -11.46 (-4.96%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

23 24 Next >

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

October 16, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Why NASDAQ:ALNY qualifies as a high growth stock. ↗

October 15, 2024

Why ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) qualifies as a high growth stock.

Via Chartmill

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

October 11, 2024

Via Benzinga

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

October 09, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today ↗

September 30, 2024

Via Benzinga

Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗

September 26, 2024

Via Benzinga

Market Whales and Their Recent Bets on ALNY Options ↗

August 30, 2024

Via Benzinga

Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio? ↗

October 06, 2024

Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop.

Via Benzinga

Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗

October 03, 2024

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible...

Via Benzinga

Topics Intellectual Property

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

September 29, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today ↗

August 26, 2024

Via Benzinga

How Is The Market Feeling About Alnylam Pharmaceuticals? ↗

August 06, 2024

Via Benzinga

Alnylam to Webcast TTR Investor Day

September 26, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

Alnylam Stock Soars 65%: Find Out What’s Behind the Gains

September 12, 2024

Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug.

Via MarketBeat

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years ↗

September 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 02, 2024

Via Benzinga

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles ↗

August 30, 2024

Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented...

Via Benzinga

Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations ↗

August 30, 2024

The company is hoping to rival Pfizer's approved treatment for cardiomyopathy.

Via Investor's Business Daily

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

August 30, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

August 28, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years ↗

August 07, 2024

Via Benzinga

The 3 Best Gene Editing Stocks to Buy in August 2024 ↗

August 07, 2024

These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.

Via InvestorPlace

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

August 07, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗

August 06, 2024

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.

Via Investor's Business Daily

DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio? ↗

August 04, 2024

Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H....

Via Benzinga

Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday ↗

August 01, 2024

Via Benzinga

Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

August 01, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗

July 22, 2024

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.